Filippatos GS - Search Results

1

Cachexia: common, deadly, with an urgent need for precise definition and new therapies.

Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Lainscak M, et al. Among authors: filippatos gs. Am J Cardiol. 2008 Jun 2;101(11A):8E-10E. doi: 10.1016/j.amjcard.2008.02.065. Am J Cardiol. 2008. PMID: 18514632

2

Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia.

Filippatos GS, Kanatselos C, Manolatos DD, Vougas B, Sideris A, Kardara D, Anker SD, Kardaras F, Uhal B. Filippatos GS, et al. Int J Cardiol. 2003 Jul;90(1):107-13. doi: 10.1016/s0167-5273(02)00535-1. Int J Cardiol. 2003. PMID: 12821225

3

B-type natriuretic peptide serum levels in acute heart failure.

Filippatos GS, Anker SD, Kardaras F. Filippatos GS, et al. Eur Heart J. 2004 Jun;25(12):1085; author reply 1085-6. doi: 10.1016/j.ehj.2004.03.027. Eur Heart J. 2004. PMID: 15191781 No abstract available.

4

Pathophysiology of peripheral muscle wasting in cardiac cachexia.

Filippatos GS, Anker SD, Kremastinos DT. Filippatos GS, et al. Curr Opin Clin Nutr Metab Care. 2005 May;8(3):249-54. doi: 10.1097/01.mco.0000165002.08955.5b. Curr Opin Clin Nutr Metab Care. 2005. PMID: 15809526 Review.

5

Pathophysiologic targets in the early phase of acute heart failure syndromes.

Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Gheorghiade M, et al. Among authors: filippatos g. Am J Cardiol. 2005 Sep 19;96(6A):11G-17G. doi: 10.1016/j.amjcard.2005.07.016. Am J Cardiol. 2005. PMID: 16196154 Review.

6

Acute heart failure syndromes: current state and framework for future research.

Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L; International Working Group on Acute Heart Failure Syndromes. Gheorghiade M, et al. Circulation. 2005 Dec 20;112(25):3958-68. doi: 10.1161/CIRCULATIONAHA.105.590091. Circulation. 2005. PMID: 16365214 No abstract available.

7

Prognosis and therapy approaches of cardiac cachexia.

Springer J, Filippatos G, Akashi YJ, Anker SD. Springer J, et al. Curr Opin Cardiol. 2006 May;21(3):229-33. doi: 10.1097/01.hco.0000221585.94490.09. Curr Opin Cardiol. 2006. PMID: 16601462 Review.

8

Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.

Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT. Adamopoulos S, et al. Among authors: filippatos gs. Am J Cardiol. 2006 Jul 1;98(1):102-6. doi: 10.1016/j.amjcard.2006.01.068. Epub 2006 May 6. Am J Cardiol. 2006. PMID: 16784930 Clinical Trial.

9

Decompensated heart failure and cachexia: Is it time to legalize anabolics?

Filippatos G, Rauchhaus M, Anker SD. Filippatos G, et al. Int J Cardiol. 2006 Jul 28;111(1):185-6. doi: 10.1016/j.ijcard.2006.06.002. Epub 2006 Jul 7. Int J Cardiol. 2006. PMID: 16828897 No abstract available.

10

Congestion in acute heart failure syndromes: an essential target of evaluation and treatment.

Gheorghiade M, Filippatos G, De Luca L, Burnett J. Gheorghiade M, et al. Am J Med. 2006 Dec;119(12 Suppl 1):S3-S10. doi: 10.1016/j.amjmed.2006.09.011. Am J Med. 2006. PMID: 17113398 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

777 results

Search Page

Filters